Suzetrigine FDA Approval: A Transformative Milestone in Pain Management
Abstract
The FDA approval of Suzetrigine (Journaux) marks a significant advancement in the field of pain management, particularly in the realm of non-opioid alternatives for acute pain relief [1]. For over two decades, no novel drug class has emerged to challenge the dominance of opioids in treating acute pain, despite the pressing need for safer options. Suzetrigine's unique mechanism of action, favorable safety profile, and potential role in acute and neuropathic pain make it a game-changer in clinical practice. This commentary explores the significance of Suzetrigine's approval, its integration into pain management, and the broader implications for patients and healthcare providers.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.